OBiO Tech(SH:688238) Zhong Guo Zheng Quan Bao·2025-12-19 00:38Core Viewpoint - The company, He Yuan Bio, has established itself as a leader in the cell and gene therapy (CGT) industry by leveraging strong technological capabilities and strategic focus, aiming to enhance its competitiveness and market penetration in the regenerative medicine sector [1][10]. Group 1: Company Overview - He Yuan Bio, founded in 2013, specializes in providing integrated CRO/CDMO services for cell and gene therapy research and drug development [2]. - The company has developed two core technology clusters: carrier development technology and production process and quality control technology for cell and gene therapy [1][2]. - As the first CGT company listed on the Sci-Tech Innovation Board, He Yuan Bio has been pivotal in the transition of China's biopharmaceutical industry from a follower to a leader [1]. Group 2: Technological Innovation - The company has made significant investments in R&D, with R&D expenses reaching 34.66 million yuan in the first three quarters of 2025, accounting for 19.22% of its revenue [3]. - He Yuan Bio has established comprehensive technology platforms, including molecular biology, virus packaging, and cell function research, achieving leading levels in key areas such as viral vector technology [2][3]. - The integration of AI technology into drug development processes has been a focus, with the establishment of an intelligent R&D system that enhances efficiency [4]. Group 3: Market Position and Client Base - He Yuan Bio has built a robust client base, collaborating with over 14,700 research laboratories and managing more than 600 CDMO projects, including five Phase III clinical projects [5]. - The company emphasizes the importance of deep technical insights and precise control over process details as core values in its CRO and CDMO services [5]. Group 4: Future Development and Expansion - The company is expanding into the regenerative medicine sector by establishing a wholly-owned subsidiary, He Yuan He Mei, to address challenges in cell safety and traceability [8]. - The company’s production base in Lingang has commenced operations, featuring 11 GMP vector production lines and 18 GMP cell production lines, positioning it among the top in the international industry [6]. - He Yuan Bio aims to enhance its international presence by supporting domestic clients in obtaining overseas IND approvals and facilitating the licensing of proprietary technologies [9]. Group 5: Commitment to Health and Innovation - The company is committed to empowering cell and gene therapy to improve public health, focusing on innovation and collaboration to drive high-quality development in the CGT field [10].